Ultragenyx Pharmaceutical Inc.RARE

Market cap

$3.2B

P/E ratio

	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	24	94	161	100	113	434	714	308	133	214	174
Marketable securities, current	163	343	219	134	346	643	488	433	615	364	436
Total cash & short-term investments	187	437	380	234	460	1,077	1,202	740	748	577	610
Accounts receivable, net	-	-	-	5	13	33	23	28	40	73	122
Inventories	-	-	-	1	7	12	13	16	27	34	45
Total current assets	193	450	402	270	522	851	1,295	857	884	732	817
Property, plant and equipment, net	3	7	17	22	20	44	74	141	260	291	266
Marketable securities, non-current	-	99	118	10	-	5	11	259	149	200	135
Total non-current assets	5	109	139	221	197	284	464	666	662	759	686
Total assets	198	560	541	491	720	1,135	1,760	1,522	1,545	1,491	1,503
Accounts payable	5	3	5	9	12	13	13	17	43	42	39
Total current liabilities	13	28	60	71	75	103	190	181	261	280	344
Total non-current liabilities	1	1	6	36	36	378	416	418	932	935	897
Total liabilities	13	28	67	107	111	482	605	600	1,193	1,216	1,241
Common stock and paid-in capital	324	817	1,004	1,222	1,640	2,087	2,773	2,998	3,140	3,662	4,213
Retained earnings	-139	-285	-531	-833	-1,030	-1,433	-1,620	-2,074	-2,781	-3,388	-3,957
Stockholders' equity	185	531	474	383	609	654	1,154	923	352	275	255
Working capital	-	-	-